retatrutide phase 3 2025 triple agonist glp-1 gip glucagon Vitality Medical | Big update in the weight loss world 👏 The FDA has officially approved a new higher-dose semaglutide option, increasing the maximum weekly Services (List) | Luxe Vitality

GLP-1 medications have gained prominence in weight management, with clinical trials showing significant metabolic benefits

In patients with type 2 diabetes mellitus, treatment with semaglutide injection 1 mg resulted in reductions in glucose in terms of absolute change from baseline and relative reduction compared to placebo of 29 mg/dL (22%) for fasting glucose, 74 mg/dL (36%) for 2-hour postprandial glucose and 30 mg/dL (22%) for mean 24-hour glucose concentration

Disclaimer: This blog post is for informational purposes only and does not constitute medical advice

Study: Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial